

# Venkatraman E Seshan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6825576/publications.pdf>

Version: 2024-02-01

48  
papers

3,347  
citations

279798

23  
h-index

254184

43  
g-index

50  
all docs

50  
docs citations

50  
times ranked

7891  
citing authors

#	ARTICLE	IF	CITATIONS
1	FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. <i>Nucleic Acids Research</i> , 2016, 44, e131-e131.	14.5	809
2	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. <i>Nature Biotechnology</i> , 2018, 36, 847-856.	17.5	564
3	Mitochondrial DNA copy number variation across human cancers. <i>ELife</i> , 2016, 5, .	6.0	384
4	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	12.8	212
5	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1417-1428.	3.6	165
6	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	21.4	139
7	Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. <i>JAMA Oncology</i> , 2021, 7, 739.	7.1	125
8	Asynchronous fate decisions by single cells collectively ensure consistent lineage composition in the mouse blastocyst. <i>Nature Communications</i> , 2016, 7, 13463.	12.8	122
9	The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. <i>Nature Cell Biology</i> , 2015, 17, 81-94.	10.3	97
10	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	7.0	85
11	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	6.2	81
12	Comparing ROC curves derived from regression models. <i>Statistics in Medicine</i> , 2013, 32, 1483-1493.	1.6	62
13	Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx. <i>International Journal of Cancer</i> , 2019, 145, 3152-3162.	5.1	48
14	NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12034-12039.	7.1	41
15	HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. <i>Nature Communications</i> , 2018, 9, 4345.	12.8	40
16	Contralateral breast cancers: Independent cancers or metastases?. <i>International Journal of Cancer</i> , 2018, 142, 347-356.	5.1	37
17	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
18	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. <i>Journal of Experimental Medicine</i> , 2014, 211, 1379-1391.	8.5	32

#	ARTICLE	IF	CITATIONS
19	Clonal relationships between lobular carcinoma in situ and other breast malignancies. Breast Cancer Research, 2016, 18, 66.	5.0	32
20	BET Inhibition-Induced GSK3 <sup>β</sup> Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. Cell Reports, 2018, 24, 2155-2166.	6.4	31
21	TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. Npj Breast Cancer, 2016, 2, 16009.	5.2	26
22	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	8.2	26
23	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer Journal, 2018, 8, 60.	6.2	25
24	Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering. Genome Medicine, 2020, 12, 110.	8.2	22
25	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. European Journal of Cancer, 2020, 126, 78-90.	2.8	21
26	Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. JCI Insight, 2019, 4, .	5.0	17
27	Identifying Etiologically Distinct Subtypes of Cancer: A Demonstration Project Involving Breast Cancer. Cancer Medicine, 2015, 4, 1432-1439.	2.8	15
28	Estimating the Probability of Clonal Relatedness of Pairs of Tumors in Cancer Patients. Biometrics, 2018, 74, 321-330.	1.4	8
29	Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma. Journal of the American Statistical Association, 2017, 112, 54-63.	3.1	7
30	Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL).. Journal of Clinical Oncology, 2020, 38, e20018-e20018.	1.6	5
31	Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS) Tj ETQq1 1 0.784314 rgBT /Overl Diseases, 2022, 75, e774-e782.	5.8	5
32	Testing clonal relatedness of two tumors from the same patient based on their mutational profiles: update of the <i>Clonality</i> R package. Bioinformatics, 2019, 35, 4776-4778.	4.1	4
33	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. Blood, 2016, 128, 2955-2955.	1.4	4
34	RE: "A MULTINOMIAL REGRESSION APPROACH TO MODEL OUTCOME HETEROGENEITY". American Journal of Epidemiology, 2018, 187, 1129-1130.	3.4	2
35	An EM algorithm to improve the estimation of the probability of clonal relatedness of pairs of tumors in cancer patients. BMC Bioinformatics, 2019, 20, 555.	2.6	2
36	Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data. Biometrics, 2021, 77, 283-292.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Characterization of patients with multiple primary tumors.. Journal of Clinical Oncology, 2020, 38, 1502-1502.	1.6	2
38	Validity of a method for identifying disease subtypes that are etiologically heterogeneous. Statistical Methods in Medical Research, 2021, 30, 2045-2056.	1.5	1
39	Understanding the genomic underpinnings of metastatic chromophobe renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 513-513.	1.6	1
40	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 3655-3655.	1.4	1
41	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer Journal, 2022, 12, 29.	6.2	1
42	Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy.. Journal of Clinical Oncology, 2022, 40, TPS4616-TPS4616.	1.6	1
43	Gene-expression profiling to demonstrate select neutrophils from breast cancer patients versus healthy women as cytotoxic against breast cancer cells via novel chemokine-mediated mechanisms.. Journal of Clinical Oncology, 2014, 32, 11086-11086.	1.6	0
44	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. Blood, 2016, 128, 4119-4119.	1.4	0
45	Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma. Blood, 2016, 128, 293-293.	1.4	0
46	Prognostic relevance of tumor sequencing in metastatic lung adenocarcinomas.. Journal of Clinical Oncology, 2018, 36, 9049-9049.	1.6	0
47	Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas.. Journal of Clinical Oncology, 2019, 37, 9113-9113.	1.6	0
48	Evaluating the association between clonal hematopoiesis and germline pathogenic and likely pathogenic variants in cancer predisposition genes.. Journal of Clinical Oncology, 2020, 38, 1535-1535.	1.6	0